Elisabeth Leiderman has joined Complexa as chief business officer. She was most recently senior vice president and head of corporate development for Fortress Biotech (NASDAQ: [[ticker:FBIO]]). Berwyn, PA-based Complexa’s lead drug candidate, CXA-10, is in Phase 2 testing for focal segmental glomerulosclerosis and pulmonary arterial hypertension.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
